Literature DB >> 18710423

Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors.

Miho Kanda1, Ryosuke Tateishi, Haruhiko Yoshida, Takahisa Sato, Ryota Masuzaki, Takamasa Ohki, Jun Imamura, Tadashi Goto, Hideo Yoshida, Keisuke Hamamura, Shuntaro Obi, Fumihiko Kanai, Shuichiro Shiina, Masao Omata.   

Abstract

BACKGROUND: Extrahepatic metastasis of hepatocellular carcinoma (HCC) is of growing importance as the survival of patients has been improved owing to advances in treatments to intrahepatic lesions.
METHODS: To elucidate the incidence and risk factors of extrahepatic metastasis of HCC, we enrolled 1573 (1131 treatment-naïve and 442 previously treated on referral) patients with HCC without extrahepatic tumour spread treated at the authors' department between 1990 and 2003. Patients received medical treatment including percutaneous ablation and transcatheter arterial chemoembolization, and followed by dynamic computed tomography (CT) or magnetic resonance imaging (MRI) and tumour markers every 3-4 months. Extrahepatic metastasis was diagnosed by plain X-ray, CT, MRI and scintigraphy. Clinical parameters at the time of treatment to intrahepatic lesions were evaluated as a predictor of subsequent extrahepatic metastasis among the 1131 treatment-naïve patients by Cox's proportional hazard model.
RESULTS: During the average observation period of 3.9 years, extrahepatic metastasis was diagnosed in 123 in the treatment-naïve and 53 in the patients treated previously. The incidence rate of extrahepatic metastasis, as detected during the lifetime after medical treatment of HCC, was approximately 13% at 5 years. Multivariate analysis with Cox proportional hazard model revealed that positivity for viral markers, lager tumour diameter, multiple tumour nodules, presence of vascular tumour invasion and elevated tumour markers were associated with the development of extrahepatic metastasis.
CONCLUSION: The incidence of extrahepatic metastasis of HCC diagnosed during clinical course was not frequent. Advanced intrahepatic lesions, presence of vascular tumour invasion, elevated tumour markers and presence of viral hepatitis were risk factors for extrahepatic metastasis.

Entities:  

Mesh:

Year:  2008        PMID: 18710423     DOI: 10.1111/j.1478-3231.2008.01864.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  47 in total

1.  Late retroperitoneal recurrence of hepatocellular carcinoma 12 years after initial diagnosis.

Authors:  Tiffany Cho-Lam Wong; Ka-Fai To; Simon See-Ming Hou; Sidney Kam-Hung Yip; Chi-Fai Ng
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

2.  Transarterial embolization of metastatic mediastinal hepatocellular carcinoma.

Authors:  Chia-Chang Chen; Hong-Zen Yeh; Chi-Sen Chang; Chung-Wang Ko; Han-Chung Lien; Chun-Ying Wu; Siu-Wan Hung
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

Review 3.  Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective.

Authors:  Peter Gibbs; Jeanne Tie; Lourens Bester
Journal:  Hepat Oncol       Date:  2015-04-20

4.  Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan.

Authors:  Ji Eun Lee; Jae Young Jang; Soung Won Jeong; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So Young Jin; Deuk Lin Choi
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

5.  Pure transcatheter arterial chemoembolization therapy for intrahepatic tumors causes a shrink in pulmonary metastases of hepatocellular carcinoma.

Authors:  Huiyong Wu; Wei Zhao; Shuguang Liu; Jinsong Zheng; Guanglei Ji; Yinfa Xie
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis.

Authors:  I-Cheng Lee; Teh-Ia Huo; Yi-Hsiang Huang; Yee Chao; Chung-Pin Li; Pui-Ching Lee; Jen-Huey Chiang; Chien-Wei Su; Keng-Hsin Lan; Chih-Ming Yang; Jaw-Ching Wu; Han-Chieh Lin; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2011-11-30       Impact factor: 6.047

7.  Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.

Authors:  Daniele Santini; Francesco Pantano; Ferdinando Riccardi; Giovan Giuseppe Di Costanzo; Raffaele Addeo; Francesco Maria Guida; Mariella Spalato Ceruso; Sandro Barni; Paola Bertocchi; Sara Marinelli; Paolo Marchetti; Antonio Russo; Mario Scartozzi; Luca Faloppi; Matteo Santoni; Stefano Cascinu; Evaristo Maiello; Franco Silvestris; Marco Tucci; Toni Ibrahim; Gianluca Masi; Antonio Gnoni; Alessandro Comandone; Nicola Fazio; Alessandro Conti; Ilaria Imarisio; Salvatore Pisconti; Elisa Giommoni; Saverio Cinieri; Vincenzo Catalano; Vincenzo Ostilio Palmieri; Giovanni Infante; Michele Aieta; Antonio Trogu; Cosmo Damiano Gadaleta; Anna Elisabetta Brunetti; Vito Lorusso; Nicola Silvestris
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

8.  18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma.

Authors:  Hironori Ochi; Masashi Hirooka; Atsushi Hiraoka; Yohei Koizumi; Masanori Abe; Ichiro Sogabe; Yoshihiro Ishimaru; Keizou Furuya; Masao Miyagawa; Hideki Kawasaki; Kojiro Michitaka; Yasutsugu Takada; Teruhito Mochizuki; Yoichi Hiasa
Journal:  Mol Clin Oncol       Date:  2014-06-25

Review 9.  Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Simone Conci; Alessandro Valdegamberi; Marco Vitali; Francesca Bertuzzo; Michela De Angelis; Guido Mantovani; Calogero Iacono
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

10.  Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.

Authors:  Martha M Kirstein; Torsten Voigtländer; Nora Schweitzer; Jan B Hinrichs; Jens Marquardt; Marcus-Alexander Wörns; Roman Kloeckner; Thorben W Fründt; Harald Ittrich; Frank Wacker; Thomas Rodt; Michael P Manns; Henning Wege; Arndt Weinmann; Arndt Vogel
Journal:  United European Gastroenterol J       Date:  2017-06-20       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.